Urinary Patient Articles & Analysis
5 news found
Lipella Pharmaceuticals Inc. said it saw positive top-line results from its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis. The biotechnology company said its next step will be to communicate with the Food and Drug Administration on the study’s results and the pathway forward to seeking regulatory approval ...
MEDICA , the largest international fair in the medical technology sector, will hold a new edition from November 18 to 21, 2019 in Düsseldorf (Germany) . The fair in the 2019 edition will welcome the visit of 120,000 people and will be attended by 5,100 exhibitors presenting their latest products and developments, among which there will be well-known companies, as well as young start-ups ...
Neuspera Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it will begin enrollment in its pivotal clinical trial (SANS-UUI), a single-arm study that will enroll 145 patients at 25 sites globally. The study will evaluate the safety and efficacy of Neuspera’s Nuvella™ system designed to treat overactive bladder ...
Bluewind Medical, Ltd., developer of the innovative RENOVA iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced the successful completion of patient enrollment in the OASIS pivotal clinical study that will be the basis by which the company will seek US-FDA (Food & Drug Administration) marketing clearance in the United States. OASIS is a ...
The idea is simple: when a patient has a bacterial infection, doctors should find out what kind of bacteria it is so they can give the most effective treatment. But growing bacteria in a lab to identify it takes hours to days. That means doctors have to make their best guess, and because there are dozens of possible strains, they guess wrong up to a third of the time. Seattle biotech startup ID ...